Wall Street analysts expect Aduro BioTech Inc (NASDAQ:ADRO) to report $3.88 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Aduro BioTech’s earnings. The lowest sales estimate is $3.75 million and the highest is $4.10 million. Aduro BioTech reported sales of $3.77 million during the same quarter last year, which indicates a positive year over year growth rate of 2.9%. The company is expected to issue its next earnings report on Tuesday, May 1st.
On average, analysts expect that Aduro BioTech will report full-year sales of $19.89 million for the current year, with estimates ranging from $15.00 million to $25.10 million. For the next fiscal year, analysts expect that the business will post sales of $32.19 million per share, with estimates ranging from $14.80 million to $55.10 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Aduro BioTech.
Aduro BioTech (NASDAQ:ADRO) last posted its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.01. Aduro BioTech had a negative net margin of 532.88% and a negative return on equity of 37.86%. The firm had revenue of $3.76 million for the quarter, compared to the consensus estimate of $4.32 million.
Several equities analysts have recently issued reports on ADRO shares. BidaskClub upgraded shares of Aduro BioTech from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 23rd. Zacks Investment Research upgraded shares of Aduro BioTech from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a report on Tuesday, March 6th. HC Wainwright set a $10.00 price objective on shares of Aduro BioTech and gave the company a “buy” rating in a report on Friday, March 2nd. Bank of America cut their price target on shares of Aduro BioTech from $9.00 to $8.00 and set an “underperform” rating on the stock in a report on Friday, March 2nd. Finally, ValuEngine downgraded shares of Aduro BioTech from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $14.50.
In other Aduro BioTech news, insider Stephen T. Isaacs sold 40,000 shares of the company’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $8.91, for a total value of $356,400.00. Following the sale, the insider now owns 245,746 shares in the company, valued at approximately $2,189,596.86. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Elsas Andrea Van sold 6,874 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $6.48, for a total value of $44,543.52. Following the completion of the sale, the insider now owns 216,669 shares in the company, valued at approximately $1,404,015.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 118,925 shares of company stock worth $1,011,936. 6.60% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC purchased a new position in shares of Aduro BioTech during the 4th quarter valued at approximately $1,309,000. Wells Fargo & Company MN lifted its position in shares of Aduro BioTech by 111.5% during the 3rd quarter. Wells Fargo & Company MN now owns 72,854 shares of the biotechnology company’s stock valued at $776,000 after buying an additional 38,415 shares in the last quarter. Two Sigma Investments LP purchased a new position in shares of Aduro BioTech during the 4th quarter valued at approximately $592,000. Virtus Fund Advisers LLC purchased a new position in shares of Aduro BioTech during the 4th quarter valued at approximately $321,000. Finally, Vident Investment Advisory LLC lifted its position in shares of Aduro BioTech by 40.4% during the 4th quarter. Vident Investment Advisory LLC now owns 154,140 shares of the biotechnology company’s stock valued at $1,156,000 after buying an additional 44,325 shares in the last quarter. Institutional investors and hedge funds own 44.91% of the company’s stock.
Shares of ADRO remained flat at $$7.10 during mid-day trading on Monday. 198,982 shares of the stock traded hands, compared to its average volume of 590,069. Aduro BioTech has a 12-month low of $5.82 and a 12-month high of $14.05. The firm has a market capitalization of $603.50, a P/E ratio of -4.98 and a beta of 2.07.
Aduro BioTech Company Profile
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.